Penumbra (PEN) Current Deferred Revenue (2022)
Penumbra (PEN) reported Current Deferred Revenue of $9.6 million for Q2 2022, up 28.0% on a QoQ basis from $7.5 million in Q1 2022.
Penumbra (PEN) has 1 years of Current Deferred Revenue data on file, last reported at $9.6 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 7.50 Mn |